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Introduction
•It is ever more critical for cell based therapy to be 
delivered by a well-designed, data driven bioprocess 
•A Quality by Design (QbD) approach allowed the 
combined effects of multiple process inputs to be 
evaluated at small scale for a selected unit operation 
– centrifugation.
•Linking an ultra scale-down approach with the 
manufacturing scale process allows the feasibility of 
the cell-product production method to be evaluated.
•An array of  scaled-down engineering tests and 
biological analyses were performed on a prostate 
cancer vaccine cell candidate with a view to 
reducing cell-growth constraints and determine cell 
responses to processing. 
Principles of whole cell based vaccine 
therapy
• A number of immortalised prostate cell lines, once 
harvested and irradiated, are administered to the 
patient.
• These cells stimulate and immunogenic response, 
triggering a cascade effect which results in the 
creation and presentation of anti-prostate cancer 
cytotoxic T lymphocytes.   
Product Process Flow Sheet
•Cell culture utilises cell factories for adherent 
monolayer growth, enzymatic harvest and numerous 
centrifugation driven wash stages. 
Experimental Findings
• A Design Of Experiments (DOE) study was 
created to establish the key process inputs and 
their subsequent effects on the target cells within 
batch centrifugation.
•The use of this approach offered an insight into 
parameter interactions, offering a more in depth 
analysis with the need for far less experimental 
runs.
•Goal – to establish a window of operation with 
relation to the three processing parameters; 
Relative Centrifugal Force (RCF), Spin Time and 
Pre-processing Hold Time, for the efficient and 
effective bioprocessing of whole cell therapies. 






• Cell lines display an increase in cell 
membrane damage as both centrifugal force 
and spin time increase. The addition of a 2 hour 
pre-processing ambient hold time, such as may 
occur during large scale processing, results in 






































Processed @ 10000 x g, 30 mins after a 1h hold time
•The effect of applied RCF for a given spin time is 
less evident within size distribution plots taken pre 
and post processing.
•Small decreases of less than 10% were observed 
in cell size evaluation, with intense cell compaction 
forces thought to be responsible
•Surface marker phenotype analysis by quantitative 
flow cytometry suggests that the application of 
extreme centrifugation conditions does have a 
significant effect on the selected cell surface marker 
profile, although small in comparison to cell integrity 
loss.
•The above examples are for extremes outside the 
normal operating window. This is deliberately to help 
evaluate cell properties and aid in cell line selection.
•Processing conditions that are sufficient to recover 
cells but lead to a loss of integrity, especially if the 
cells have been held, have little or no effect on cell 
size and surface marker phenotype. 
Conclusions
•The impact of centrifugation upon a whole cell 
vaccine has been quantified, identifying key critical 
process parameters (CPPs) associated with key cell 
quality attributes.
•CPP interactions are displayed within this study type, 
allowing the construction of a design space for 
centrifugation based processing.
